Gilead Adefovir Patients Should Be Monitored Every Four Weeks - FDA Cmte.
Executive Summary
Gilead's adefovir dipivoxil patients should be monitored every four to eight weeks following initial dosing, FDA's Antiviral Drug Products Advisory Committee recommended during its Aug. 6 meeting
You may also be interested in...
Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)
Gilead Hepsera Launch: Lamivudine-Resistant Hep B Is First Target
Gilead's roll-out of Hepsera should be helped by a readily identifiable population of approximately 12,000 hepatitis B patients who are resistant to lamivudine (GlaxoSmithKline's Epivir-HBV)
Gilead Hepsera Clears FDA; Hepatitis B Therapy Will Cost $440 Per Month
Gilead is launching the hepatitis B agent Hepsera (adefovir) at a wholesale acquisition cost of $440 per month